Michael Gold to Multivariate Analysis
This is a "connection" page, showing publications Michael Gold has written about Multivariate Analysis.
Connection Strength
0.390
-
Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
Score: 0.087
-
Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
Score: 0.085
-
Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
Score: 0.045
-
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
Score: 0.029
-
Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol. 1997 Jun 15; 79(12):1623-7.
Score: 0.028
-
Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997 Jan 15; 79(2):150-3.
Score: 0.027
-
Chronic rise in defibrillation threshold with a hybrid lead system. Am J Cardiol. 1996 Aug 01; 78(3):309-12.
Score: 0.027
-
Health insurance and mortality. Evidence from a national cohort. JAMA. 1993 Aug 11; 270(6):737-41.
Score: 0.022
-
Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013 Apr; 24(4):381-7.
Score: 0.021
-
Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J. 2003 May; 145(5):841-6.
Score: 0.011
-
Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
Score: 0.009